Production (Stage)
Enanta Pharmaceuticals, Inc.
ENTA
$7.50
$0.091.22%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -11.55% | -9.55% | -14.61% | -10.71% | -10.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -11.55% | -9.55% | -14.61% | -10.71% | -10.22% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -11.55% | -9.55% | -14.61% | -10.71% | -10.22% |
| SG&A Expenses | -10.21% | -4.46% | 9.38% | 12.20% | 9.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.02% | -17.97% | -12.52% | -8.88% | -0.93% |
| Operating Income | 24.58% | 22.33% | 11.31% | 7.77% | -4.92% |
| Income Before Tax | 23.87% | 21.72% | 10.08% | 7.58% | -3.83% |
| Income Tax Expenses | -235.76% | -168.83% | -161.79% | -165.72% | 531.68% |
| Earnings from Continuing Operations | 26.81% | 24.10% | 13.28% | 12.67% | -5.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.81% | 24.10% | 13.28% | 12.67% | -5.65% |
| EBIT | 24.58% | 22.33% | 11.31% | 7.77% | -4.92% |
| EBITDA | 25.50% | 22.79% | 11.48% | 8.04% | -4.88% |
| EPS Basic | 27.32% | 24.58% | 13.92% | 13.43% | -4.40% |
| Normalized Basic EPS | 25.50% | 23.30% | 12.23% | 6.64% | -4.36% |
| EPS Diluted | 27.32% | 24.58% | 13.92% | 13.43% | -4.40% |
| Normalized Diluted EPS | 25.50% | 23.30% | 12.23% | 6.64% | -4.36% |
| Average Basic Shares Outstanding | 0.71% | 0.64% | 0.79% | 0.99% | 1.26% |
| Average Diluted Shares Outstanding | 0.71% | 0.64% | 0.79% | 0.99% | 1.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |